Allena Pharmaceuticals, Inc. (ALNA:NASDAQ) Investor Relations Material

Overview

Allena Pharmaceuticals is a biopharmaceutical company that focuses on developing and distributing innovative oral enzyme therapeutics to treat a range of rare and severe metabolic and kidney disorders. The company's lead product candidate is reloxaliase, a first-of-its-kind oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by high urinary oxalate levels commonly associated with kidney stones and other serious kidney disorders. The therapeutic is in its late-stage development and, if approved, will provide a much-needed solution for a currently unmet medical need.

Frequently Asked Questions

What is Allena Pharmaceuticals, Inc.'s ticker?

Allena Pharmaceuticals, Inc.'s ticker is ALNA

What exchange is Allena Pharmaceuticals, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Allena Pharmaceuticals, Inc.'s headquarters?

They are based in Newton, Massachusetts

How many employees does Allena Pharmaceuticals, Inc. have?

There are 11-50 employees working at Allena Pharmaceuticals, Inc.

What is Allena Pharmaceuticals, Inc.'s website?

It is http://www.allenapharma.com/

What type of sector is Allena Pharmaceuticals, Inc.?

Allena Pharmaceuticals, Inc. is in the Healthcare sector

What type of industry is Allena Pharmaceuticals, Inc.?

Allena Pharmaceuticals, Inc. is in the Biotechnology industry

Who are Allena Pharmaceuticals, Inc.'s peers and competitors?

The following five companies are Allena Pharmaceuticals, Inc.'s industry peers:

- Catalyst Biosciences, Inc.

- Aclaris Therapeutics

- TRACON Pharmaceuticals

- Omeros Corp

- scPharmaceuticals